



Figure 1




	PSL AβpE3-42	Cal Hu AβpE3-42
Ec50nM	24.92	15.67

Figure 2
Binding ELISA for mouse and chimeric NT4X
(PSL peptides)




	PSL AβpE3-42 mNT4X (*A)	PSL AβpE3-42 chimeric NT4X (*B)
Ec50nM	24.92	47.08

Figure 3
Binding of humanised variants to pE3-42




	RHA/RKA *A	RHA/RKB *C	RHB/RKA *B	RHB/RKB *D	cNT4X *F	Solenzumab *E
EC ₅₀ (µg/ml)	No Binding	No Binding	0.341	0.3766	0.118	0.15

Figure 4



	RHA/RKA	RHA/RKB	RHB/RKA	RHB/RHB	cNT4X	Solineuzumab
Ec50 (ug/ml)	No Binding	No Binding	No Binding	No Binding	213.7	0.22

Figure 5



	cNT4X	RHB/RKA	RHB/RHB	mNT4X
EC50 (ug/ml)	0.2272	3.864	2.736	2.399

Figure 6




Figure 7




Figure 8




Figure 9




Figure 10




Figure 10 (continued)




Figure 11




Figure 11 (continued)

Antibody	T _m First Phase (°C)	T _m Second Phase (°C)	T _m Third Phase (°C)	T _m Average (°C)
2uM rcNT4X_SA	65	77	85	67.5
2uM rcNT4X_S7A				66
2uM mNT4X	65.3	78.5		67.8
2uM cNT4X	69.2	80.3		72.8


Antibody	Processed Av T _m (°C)
rcNT4X_S7A (MoG1/k)	66
rcNT4X_SA (MoG1/K)	67
rcNT4X_BA (MoG1/K)	71
mNT4X(G1/K)	68
cNT4X (HuG1/K)	72
MRCTrdIsoMoG1K	68

Figure 12



Samples	CNT0607 1	CNT0607 2	rcNT4XSA	rcNT4XBA	rc9D5	mNT4X	cNT4X	Commercial mAb 1	Commercial mAb 2
Retention factor K'	0.675	0.65	0.038	0.039	0.035	0.086	0.065	0.034	0.038

Figure 13



Samples	CNT0607 1	CNT0607 2	Commercial mAb 1	rcNT4XS7A
Retention factor K'	0.584	0.583	0.037	0.046

Figure 14




Figure 15




Figure 15 (continued)




Figure 16




Figure 16 (continued)






Figure 17




Antibody	IC50 (ug/ml)
rcNT4X_SA	65.5 (t/b=const)
rcNT4X_S7A	40.8 (t/b=const)
mNT4X(G1)	59.62
rcNT4X_BA	67.3 (t/b=const)
MRCTrcIso ctl	-

Figure 18




Antibody	IC50 (ug/ml)
rcNT4X_SA	88.68 (t/b=const)
rcNT4X_S7A	45.5 (t/b=const)
mNT4X(G1)	66.07 (t/b=const)
rcNT4X_BA	69.81 (t/b=const)
MRCTrcIso ctl	-

Figure 19



Antibody	IC50 (ug/ml)
rcNT4X_SA	-
rcNT4X_S7A	-
mNT4X(G1)	-
rcNT4X_BA	-
MRCTrliso ctl	-
Sol	102.2
Bap	35.9


Figure 20



Antibody	IC50 (ug/ml)
rcNT4X_SA	75.06
rcNT4X_S7A	80.42
rcNT4X_S71H	63.54
mNT4X(G1)	183.8
MRCTrcIso ctrl	-
Sol(HuG1k)	81.34

Ana4-42 (10uM) n=2


Figure 21



Antibody	IC50 (ug/ml)
rcNT4X_SA	Amb
rcNT4X_S7A	77.03
rcNT4X_S71H	35.3
mNT4X(G1)	61.56
MRCTrclso ctl	-
Sol(HuG1k)	~49.98

CalpE3-42 (5uM) n=2

Figure 22



Antibody	IC50 (ug/ml)
rcNT4X_SA	-
rcNT4X_S7A	-
rcNT4X_S71H	-
mNT4X(G1)	-
MRCTrclso ctl	-
Sol(HuG1k)	181.3

Ana1-42 (5uM) n=2

Figure 23




Figure 24




Figure 25




Figure 26

Probe trial of Morris water maze




Figure 27

